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Targeted immunotherapy, such as anti-CTLA-4 and
anti-PD-1, has proven effective in treating cancer
patients. However, despite these advances, cancer
remains the second leading cause of death in the US.
More effective strategies designed to maximize anti-
tumor CD8 T cell responses are necessary to sustain
long-term immunity. Agonist anti-OX40 and antagonist
anti-CTLA-4 mAb augment the CD8 T cell response
through different mechanisms. Therefore, we investi-
gated the additive effects of these modalities on CD8
T cell responses. Combination anti-OX40/anti-CTLA-4
therapy more effectively primed antigen-specific CD8
T cells through enhanced expansion (82% of circulating
CD8 T cells) compared to anti-OX40 (61%; P<0.05) or
anti-CTLA-4 (41%; P<0.01) alone. Dual therapy also
drove expansion of the polyclonal CD8 population.
Moreover, combination therapy induced more prolifera-
tion (Ki-67) and differentiation (granzyme B, CD127,
KLRG-1) following priming, suggesting potent additive
effects of these modalities. However, it is known that
tumors can induce T cell anergy, thereby limiting an
effective anti-tumor response. We tested whether com-
bination therapy could overcome anergy using a mouse
model in which mice are tolerant to membrane-bound
OVA. Combination anti-OX40/anti-CTLA-4 therapy
was uniquely capable of driving robust expansion (12%
of total CD8 in the spleen, vs. 2.5% anti-OX40, P<0.05,
or 1% anti-CTLA-4, P<0.01) of anergic CD8 T cells,
along with enhanced Ki-67 and granzyme B. To further
drive expansion of antigen-specific CD8 T cells
following therapy, we examined several methods of vac-
cination using nanoparticles, a Listeria monocytogenes
vector, or anti-DEC-205 mAb (all conjugated to OVA)
in the presence of anti-CD40. In anergic mice given
combination therapy, vaccination with anti-DEC-205-
OVA/anti-CD40 produced a 9-fold expansion of OT-I
CD8 T cells compared to soluble OVA alone, greater
than all other vectors combined. We next tested the effi-
cacy of combination therapy with vaccination on anergy
in a spontaneous model of prostate cancer. Combination
therapy with vaccination drove expansion (2-fold over
monotherapy, P<0.05) and differentiation (granzyme B,
KLRG-1, CD25) of both anergic tumor-specific and
polyclonal CD8 T cells. Importantly, dual therapy with
vaccination enhanced the frequency and number of
IFN-g, TNF-a, and IL-2 producing CD8 T cells. These
data indicate that anti-OX40/anti-CTLA-4 combination
therapy with vaccination can uniquely augment and
drive a robust CD8 T cell response capable of overcom-
ing anergy.
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